Advanced Code injection

Ontario Industry Updates

Lumira Capital Leads $7M Series A Financing of Edesa Biotech

MARKHAM, ON, Sept. 20, 2017 Edesa Biotech Inc., a clinical-stage private company announced today the completion of a $7 million Series A financing.  The internationally syndicated investment was led by Lumira Capital and included participation from Pharmascience Inc., Inveready Technology Investment Group and a number of Canadian family offices.

CAAP Company: Proteorex Presents at IndieBio's Demo Day

IndieBio is the world’s largest biotechnology accelerator, and Proteorex presented as part of the Batch 5 Cohort. The company is is developing small molecule drugs for challenging targets implicated in diseases with the highest unmet need. 

The presentation was delivered in San Francisco this September 14th by Dr. Marc Adler, Co-Founder and Technology Director of Proteorex.

Mars Innovation and Evotec Ag Establish Academic Bridge “Lab150” in Toronto

MaRS Innovation and Evotec AG today announced the launch of “LAB150”.  This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation.

Lab150 is a joint effort by MaRS Innovation and Evotec AG selection and acceleration of early-stage drug discovery projects originating from leading academic institutions and teaching hospitals in Toronto (Canada)

Quick Biotechnology Survey on Employee Perception of the Workplace

Biotechnology Focus, in collaboration with Stratford Managers Corporation, wants to learn more about employee perception of their workplace.

Please complete the survey in its entirety before September 22nd. The responses will be included in in a sector report that will be featured in the October/November issue of Biotechnology Focus.

To start the Survey click here

Seed Funding Available: Weston Brain Institute Launches Rapid Response - Canada 2018 Program for Parkinson’s & Related Diseases

Program Overview

Seed funding for novel, high-risk, high-reward translational research to accelerate the development of safe and effective treatments for neurodegenerative diseases of aging. Funding up to $200,000 over up to 18 months

Letter of Intent Deadline: December 4, 2017 at 2pm EST

Program Information Session: October 10, 2017 at 1pm EDT (Register here)

Application Form

CAAP Company: MyndTec Announces 510(k) Clearance for MyndMove® Therapy for Individuals with Upper Extremity Paralysis

MyndTec, an award-winning Canadian medical technology company announced today it has received 510(k) clearance to market its landmark product MyndMove®.  MyndTec is a pioneer in the treatment of arm and hand paralysis caused by stroke or spinal cord injury. 

“This is a major milestone in the evolution of our company. We are delighted that we can now offer this life-changing therapy to patients in the U.S. with upper extremity paralysis.”
— Dr. Milos R. Popovic, MyndTec Founder

For the full press release click here

CAAP Companies: Komodo OpenLab & KE2 Technologies Advance to the Top 10 in the Interface Health Challenge

The 3rd annual INTERFACE HEALTH CHALLENGE X 2017 (#IHCX2017 competition seeks to find the world’s most innovative digital health start-ups.

This year CAAP companies KomodoOpenLab and KE2 Technologies have made it to the Top 10, guaranteeing a cash prize and putting them in contention for the $40K 1st Prize.

CAAP Company: SensOR Medical Announced as National Winner of the James Dyson Award

CAAP company SensOR Medical's ForceFilm technology, a thin add-on for minimally invasive surgical (MIS) instruments that provides surgeons with a digital sense of touch to help improve surgical safety, was selected as the Canadian James Dyson Award winner. SensOR will receive $3,400 toward ForceFilm’s development.

SensOR will now enter the International competition, where it will go up against other national winners for the ultimate $50,000 prize.

Pre-CAAP Company: Medstack & Zensurance Announce Partnership to Accelerate Digital Health Innovation

MedStack and Zensurance recently announced a partnership that will bring competitive cyber-liability insurance packages to MedStack customers. Digital health companies on MedStack's platform meet the highest levels of security and stability, qualifying them for exclusive cybersecurity insurance packages from Zensurance.

Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Development and Manufacturing Business for US $290 Million

Therapure Biopharma Inc. today announced that a joint venture between 3SBio Inc., a leading global biotechnology company, and CPE Funds has entered into an agreement to acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market for US$290 million, subject to certain adjustments.

Call for Applications - Industry Innovation Partnership Program, Up to $3M Available

The Centre for Aging + Brain Health Innovation (CABHI) announced today the second round of funding available through its Industry Innovation Partnership Program (I2P2). This program is designed to enable successful applicant companies worldwide to accelerate the evaluation and adoption of their innovative products and services that can help to address the needs of aging adults. In total, up to $3 million CAD in funding will be available for solution testing and validation. 

Reliq Health Announces Go-Live with 30,000 Patient Primary Care Group in Texas

VANCOUVER, BC, August 17, 2017. Reliq Health Technologies Inc. a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community‐Based Healthcare, is pleased to announce the golive of remote patient monitoring, care coordination and telemedicine platform with their Rio Grande Valley Health Alliance in McAllen, Texas.